Accessible Search Form           Advanced Search

Richard W. Childs, M.D.


Principal Investigator thumbnail image

Richard W. Childs
Senior Investigator

P: +1 301 451 7128
F: +1 301 480 2664

Full Publications Listing

Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer.
Cherkasova E, Malinzak E, Rao S, Takahashi Y, Senchenko VN, Kudryavtseva AV, Nickerson ML, Merino M, Hong JA, Schrump DS, Srinivasan R, Linehan WM, Tian X, Lerman MI, Childs RW.
Oncogene. 2011 Nov 24;30(47):4697-706.
[Text Abstract on PubMed]

Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R.
Blood. 2009 Jun 11;113(24):6120-7.
[Text Abstract on PubMed]

Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.
Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Tawab A, Abdul T, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW.
J. Clin. Invest. 2008 Mar;118(3):1099-109.
[Text Abstract on PubMed]

Mitochondrial DNA sequence heterogeneity of single CD34+ cells after nonmyeloablative allogeneic stem cell transplantation.
Yao YG, Childs RW, Kajigaya S, McCoy, Young NS.
Stem Cells. 2007 Oct;25(10):2670-6.
[Text Abstract on PubMed]

Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, Zeilah J, Kurlander R, Srinivasan R, Childs R, Hensel N, Barrett AJ.
Leukemia. 2007 Oct;21(10):2145-52.
[Text Abstract on PubMed]

Perforin gene mutations in patients with acquired aplastic anemia.
Solomou EE, Gibellini F, Stewart B, Malide D, Berg M, Visconte V, Green S, Childs R, Chanock SJ, Young NS.
Blood. 2007 Jun 15;109(12):5234-7.
[Text Abstract on PubMed]

Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.
Lundqvist A, McCoy JP, Samsel L, Childs R.
Blood. 2007 Apr 15;109(8):3603-6.
[Text Abstract on PubMed]

Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.
Sandmaier BM, Mackinnon S, Childs RW.
Biol. Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):87-97.
[Text Abstract on PubMed]

Immunotherapy for renal cell cancer.
Yang JC, Childs R.
J. Clin. Oncol. 2006 Dec 10;24(35):5576-83.
[Text Abstract on PubMed]

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R.
Cancer Res. 2006 Jul 15;66(14):7317-25.
[Text Abstract on PubMed]

Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis.
Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D, Quezado M, Kleiner D, Rucker S, Espina V, Whiteley G, Liotta L, Petricoin E, Pittaluga S, Hitt B, Barrett AJ, Rosenblatt K, Childs RW.
Exp. Hematol. 2006 Jun;34(6):796-801.
[Text Abstract on PubMed]

Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
Srinivasan R, Takahashi Y, McCoy JP, Espinoza-Delgado I, Dorrance C, Igarashi T, Lundqvist A, Barrett AJ, Young NS, Geller N, Childs RW.
Br. J. Haematol. 2006 May;133(3):305-14.
[Text Abstract on PubMed]

Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
Savani BN, Srinivasan R, Espinoza-Delgado I, Dorrance C, Takahashi Y, Igarashi T, Rezvani K, Lundqvist A, Barrett AJ, Childs RW.
Lancet Oncol. 2005 Oct;6(10):809-12.
[Text Abstract on PubMed]

High-dose chemotherapy and allogeneic immunotherapy.
Childs R, Srinivasan R.
Lancet. 2005 Jul 23-29;366(9482):273-5.
[Text Abstract on PubMed]

Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.
Griffith LM, McCoy, Bolan CD, Stroncek DF, Pickett AC, Linton GF, Lundqvist A, Srinivasan R, Leitman SF, Childs RW.
Br. J. Haematol. 2005 Mar;128(5):668-75.
[Text Abstract on PubMed]

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW.
Blood. 2004 Jul 1;104(1):170-7.
[Text Abstract on PubMed]

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ, Geller N, Childs R.
Br. J. Haematol. 2004 Mar;124(6):777-86.
[Text Abstract on PubMed]

In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation.
Takahashi Y, McCoy, Carvallo C, Rivera C, Igarashi T, Srinivasan R, Young NS, Childs RW.
Blood. 2004 Feb 15;103(4):1383-90.
[Text Abstract on PubMed]

Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.
Carvallo C, Geller N, Kurlander R, Srinivasan R, Mena O, Igarashi T, Griffith LM, Linehan WM, Childs RW.
Blood. 2004 Feb 15;103(4):1560-3.
[Text Abstract on PubMed]

Nonmyeloablative allogeneic immunotherapy for solid tumors.
Childs RW, Barrett J.
Annu. Rev. Med. 2004;55:459-75.
[Text Abstract on PubMed]

Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.
Bolan CD, Leitman SF, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW.
Blood. 2001 Sep 15;98(6):1687-94.
[Text Abstract on PubMed]

Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, Holland SM, Linton GF, Miller JA, Leitman SF, Read EJ, Malech HL.
N. Engl. J. Med. 2001 Mar 22;344(12):881-8.
[Text Abstract on PubMed]

Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ.
N. Engl. J. Med. 2000 Sep 14;343(11):750-8.
[Text Abstract on PubMed]

Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.
Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ.
Blood. 1999 Nov 1;94(9):3234-41.
[Text Abstract on PubMed]

Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J.
J. Clin. Oncol. 1999 Jul;17(7):2044-9.
[Text Abstract on PubMed]